Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
What impact could the FDA requirement have on the projected market size and revenue potential for roluperidone in treating negative symptoms of schizophrenia?
How does the current cash position and Q2 results support the additional R&D spend required for the confirmatory study?
Are there any contingency plans or alternative asset programs that Minerva could prioritize if roluperidone faces further regulatory hurdles?
27 days ago